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Abstract 
Background: the characteristics of 
90Y, suitable for therapy, are denoted by the lack of γ-emission. Alternative methods, using analogues 
labelled with 
111In or 
86Y, are generally applied to image 
90Y-conjugates, with some inevitable drawbacks. New generation SPECT/CT 
image systems offer improved Bremsstrahlung images. The intent of this brief communication is to show that high quality 
90Y-
Bremsstrahlung SPECT-CT images can be obtained, allowing the biodistribution of pure β-emitter therapeutical agents to be evaluated, 
also during the course of therapy. 
Methods: the hybrid system Siemens Symbia-T2 was used for the acquisition of images of a patient given 1.7 GBq of 
90Y-DOTATATE. 
The following parameters were set for SPECT: 80 (50%) and 120 (30%) keV energy windows; medium energy collimators; 128 x 128 
matrix, 64 projections (40s/step). Low-dose CT was acquired (80 mAs) for attenuation correction. Images were reconstructed with the 
OSEM 3D-Fast algorithm. 
Results: post-therapy SPECT-CT 
90Y-Bremsstrahlung images of a patient undergoing receptor peptide radionuclide therapy are 
presented. 
90Y-Bremsstrahlung images obtained are suitable for tumour and normal organ dosimetry, providing detailed information on 
biodistribution, comparable to 
111In-diagnostic images. 
Conclusions: the improved Bremsstrahlung images means that the diagnostic examinations can be used for patient recruitment and that 
dosimetry evaluation can be restricted only to treated patients. This could avoid the need for a different radionuclide or isotope to mimic 
therapy. The clinical impact might be notable, as dosimetry and toxicity information are essential in radionuclide therapy, especially in 
patients with risk factors. 
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Figure 1: Trans-axial and coronal slices of fused SPECT-CT, showing uptake in the abdominal lesion (red arrow), the kidneys (yellow arrow) 
and the spleen. Images obtained 24 h after the injection of (A) octreoscan (185 MBq), (B) 
90Y-DOTATATE (1.7 GBq).
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A 53-year old man, diabetic, with an unresectable endocrine 
pancreatic carcinoma was diagnosed with additional abdominal 
metastases as documented by CT and biopsy. In August 2007, 
scintigraphic images with octreoscan demonstrated high uptake 
in the abdominal lesions. Figure 1A shows the trans-axial and 
coronal slices of fused SPECT-CT, with uptake in the abdominal 
lesion (red arrow), kidneys and spleen. In November 2007, the 
patient underwent the first cycle of receptor peptide radionuclide 
therapy with 1.7 GBq of 
90Y-DOTATATE. 
Post-therapy SPECT-CT 
90Y-Bremsstrahlung images were 
acquired at 24 and 48 hours, with the same settings, excluding 
energy windows, as for octreoscan. The hybrid system Siemens 
Symbia T2 was used for SPECT acquisition, with medium 
energy collimators, 80 (50%) and 120 (30%) keV energy 
windows, 128 x 128 matrix, 64 projections (40 s/step). Low-
dose CT was acquired (80 mAs) and used for attenuation 
correction. Images were reconstructed with the OSEM 3D Fast 
algorithm with automatic correction for 3D response of the 
collimator. 
The
 90Y-Bremsstrahlung images obtained give more detailed 
information on biodistribution, in comparison to the 
111In-
diagnostic images, which are more suitable for tumour and 
normal organ dosimetry. Figure 1B shows the corresponding 
trans-axial and coronal slices of fused SPECT-CT as with 
octreoscan. Increased uptake in the abdominal lesion (red 
arrow) and higher uptake in the renal cortex than the medulla 
(yellow arrow) [1] can be clearly distinguished. This is consistent 
with the different distribution of DOTATATE versus octreoscan. 
The higher quality of the Bremsstrahlung images means that the 
diagnostic examination can be aimed at patient recruitment 
(suitability or not for treatment) and so restricting dosimetry 
evaluation only to treated patients. This could avoid the need for 
a tracer to mimic therapy and overcome difficulties of 
86Y 
quantification [2]. The clinical impact might be notable as 
dosimetry and toxicity information are essential in radionuclide 
therapy especially in patients with associated risk factors (e.g. 
diabetes) [3]. 
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